XSHE
002513
Market cap311mUSD
Oct 09, Last price
5.55CNY
1D
-0.18%
1Q
13.73%
Jan 2017
-65.74%
IPO
-71.46%
Name
Jiangsu Lanfeng Bio-chemical Co Ltd
Chart & performance
P/E
—
P/S
0.89
EPS
—
Div yield, %
—
Shrs. gr., 5y
-0.04%
Rev. gr., 5y
10.15%
Revenues
2.34b
+30.56%
Net income
-191m
L-24.54%
CFO
-376m
L
Dividend
Jun 13, 20170.04 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Jiangsu Lanfeng Bio-chemical Co.,Ltd is engaged in the entire process of research, development, manufacturing, and distribution of agro-chemicals and specialty chemical intermediates. Serving both domestic and global markets, the company provides a wide range of crop protection products, including various pesticides, fungicides, insecticides, and herbicides. Key offerings within their product portfolio include thiophanate-methyl, cyclohexazone, benomyl, and carbendazim. The firm's operational base is located in Xinyi, China.
Key people
Zhenhua Yang
Chairman of the Board · since 2007
Yu Liu
General Manager, Director · since 2013
Kang Chen
Secretary of the Board, Deputy General Manager · since 2007
Siyu Gu
Deputy General Manager · since 2007
Yongsheng Shen
Deputy General Manager · since 2007
Xiaomin Zhang
Deputy General Manager · since 2013
Gang Zheng
Deputy General Manager
Bin Geng
Director · since 2007
Ziqiang Gu
Director · since 2007
Ju Xiong
Director
Chunhui Gan
Independent Director · since 2013
Rengen Hua
Independent Director · since 2008
Hexiang Jia
Independent Director · since 2013
Independent Director · since 2008
Independent Director · since 2013
Shubao Sun
Independent Director · since 2008
Yi Wang
Independent Director · since 2008
Independent Director · since 2013
Headquarters & legal address
江苏新沂经济开发区苏化路1号
徐州市, JS 100000
CN
徐州市, JS 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||